AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BMO Capital Downgrades Abbvie (ABBV) to Underperform; 'Risk/Reward Skewed to the Downside'
January 29, 2018 7:34 AM ESTBMO Capital downgraded Abbvie (NYSE: ABBV) from Market Perform to Underperform with a price target of $95.00 (from $84.00).
Analyst Alex Arfaei commented, "Our thesis is unchanged, but the risk/reward in ABBV has meaningfully changed after its remarkable rise, leading us to... More
Abbvie (ABBV) PT Raised to $157 at SunTrust Robinson Humphrey; Premium Warranted
January 29, 2018 6:14 AM ESTSunTrust Robinson Humphrey raised its price target on Abbvie (NYSE: ABBV) to $157.00 (from $105.00) while maintaining a Buy rating.
Analyst John Boris said operational execution and pipeline warrant a premium.
... MoreAbbvie (ABBV) PT Raised to $130 at Cowen; Big Beat
January 26, 2018 11:16 AM ESTCowen raised its price target on Abbvie (NYSE: ABBV) to $130.00 (from $105.00) while maintaining an Outperform rating.
Analyst Steve Scala commented, "Q4 EPS and revenue well ahead of estimates. 2018 EPS guidance boosted sizably on strong operations and tax rate benefits. Plans for increasing shareholder... More
AbbVie (ABBV) Tops Q4 EPS by 4c, Raises FY18 EPS Guidance
January 26, 2018 7:53 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $1.48, $0.04 better than the analyst estimate of $1.44. Revenue for the quarter came in at $7.74 billion versus the consensus estimate of $7.53 billion.
GUIDANCE:
AbbVie sees FY2018 EPS of $7.33-$7.43, versus the consensus of $6.59.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More